MUC16 and ovarian cancer: When CA125 was combined with the biomarkers (transthyretin and apolipoprotein A1), the overall sensitivity and specificity for discriminating between ovarian cancer and healthy individuals were significantly improved in the ROC curve (Fig. 3A–C).